UCLA to host conference on revolutionary and controversial new strategy to combat HIV

August 17, 2009

WHAT: Pre-exposure prophylaxis (PrEP) is a revolutionary--and some would say controversial--new strategy for combating HIV. With PrEP, HIV-negative people take antiretroviral drugs prior to potential exposure to the virus to reduce the risk of infection. Results from PrEP clinical trials are expected within the year. UCLA's Center for HIV Identification, Prevention and Treatment Services (CHIPTS) will host "Preparing for PrEP: A Stakeholder's Dialogue," a one-day conference comprising researchers, policy makers, providers, consumers and community representatives who will explore how PrEP could impact HIV prevention efforts if it proves to be efficacious. This conference is a satellite meeting of, and precedes, the U.S. Centers for Disease Control and Prevention's 2009 National HIV Prevention Conference in Atlanta, being held from August 23 to 26.

Other conference sponsors are the National Institute of Mental Health (NIMH), the UCLA Program in Global Health, the Global Campaign for Microbicides, the Forum for Collaborative HIV Research, the Black AIDS Institute, AIDS Project LA (APLA), Community HIV/AIDS Mobilization Project (CHAMP), Project Inform, AIDS Vaccine Advocacy Coalition (AVAC), and the National Alliance of State & Territorial AIDS Directors (NASTAD)

For more details about the "Preparing for PrEP" conference, visit http://chipts.ucla.edu/events/conferences/PrEP/index.asp

WHO: WHEN: 7:30 a.m. to 3:30 p.m. Sunday, Aug. 23.

WHERE: Hyatt Regency Atlanta, 265 Peachtree Street NE, Atlanta

BACKGROUND: The Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) is a collaboration of researchers from UCLA, Charles Drew University of Medicine and Science, Friends Research Institute, RAND, and the broader Los Angeles community working to enhance our collective understanding of HIV research and to promote early detection, effective prevention, and treatment programs for HIV. Funded by the National Institute of Mental Health, CHIPTS serves as a bridge among researchers, government, service providers, and people with HIV in responding to the changes in the HIV epidemic and in shaping sound public policy. For more information, visit the Center's Web site at http://chipts.ucla.edu/
RESERVATIONS: Contact Kevin Farrell at (310) 794-6272 through Thursday, Aug. 20. After that date, please use mobile phone (707) 328-2828

MEDIA CONTACT: Enrique Rivero, UCLA Health Sciences Media Relations erivero@mednet.ucla.edu, (310) 794-2273.

On-Site: Kevin Farrell, Executive Director, CHIPTS. Mobile phone (707) 328-2828

University of California - Los Angeles

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.